Create Account | Sign In: Author or Forum

 
News  |  Journals  |  Conferences  |  Opinion  |  Articles  |  Forums  |  Twitter    
 
Category: Hematology | Neurology | Oncology | Ophthalmology | Journal

Back to Journal Articles

Drug May Improve Outcomes for CNS Lymphomas

Last Updated: September 21, 2009.

 

Study finds cytarabine addition to methotrexate improves remission rates

Share |

Comments: (0)

Tell-a-Friend

 

  Related
 
The addition of high-dose cytarabine to standard methotrexate treatment of primary central nervous system lymphomas greatly improves remission rates, according to a study published early online Sept. 20 in The Lancet to coincide with the European Cancer Organisation meeting in Berlin.

MONDAY, Sept. 21 (HealthDay News) -- The addition of high-dose cytarabine to standard methotrexate treatment of primary central nervous system lymphomas greatly improves remission rates, according to a study published early online Sept. 20 in The Lancet to coincide with the European Cancer Organisation meeting in Berlin.

As part of an open Phase II trial, Andres J.M. Ferreri, M.D., from the San Raffaele Scientific Institute in Milan, Italy, and colleagues randomly assigned 79 adults with non-Hodgkin lymphoma confined to the central nervous system, cranial nerves, or eyes to methotrexate alone or combined with cytarabine. Both treatments were accompanied by whole-brain irradiation in most cases.

After a median follow-up of 30 months, the researchers found that the complete remission rate was significantly higher in patients who received both drugs (46 versus 18 percent). After including patients with a partial response, the overall response rate remained significantly higher in the methotrexate plus cytarabine group (69 versus 40 percent). Significantly more patients in the combination group had grade 3 to 4 hematological toxicity (92 versus 15 percent), although the death rate from toxicity was not significantly different (8 versus 3 percent).

"In conclusion, the addition of high-dose cytarabine to high-dose methotrexate is associated with a remarkable outcome benefit in patients with primary central nervous system lymphoma," Ferreri and colleagues conclude. "This combination could be used as an upfront approach in patients aged 75 years and younger and with adequate hepatic and renal function, with appropriate antimicrobial prophylaxis."

Abstract
Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Copyright © 2009 ScoutNews, LLC. All rights reserved.


Previous: Patients' Mistrust Affects Use of Breast Cancer Treatments Next: Hormone Replacement Linked to Lung Cancer Deaths

Reader comments on this article are listed below. Review our comments policy.


Submit your opinion:

Name:

Email:

Location:

URL:

Remember my personal information

Notify me of follow-up comments?

advertisement.gif (61x7 -- 0 bytes)
 

Are you a Doctor, Pharmacist, PA or a Nurse?

Join the Doctors Lounge online medical community

  • Editorial activities: Publish, peer review, edit online articles.

Doctors Lounge Membership Application

 
     

 advertisement.gif (61x7 -- 0 bytes)

 

 

Useful Sites
MediLexicon
  Tools & Services: Follow DoctorsLounge on Twitter Follow us on Twitter | RSS News | Newsletter | Contact us
Copyright © 2001-2014
Doctors Lounge.
All rights reserved.

Medical Reference:
Diseases | Symptoms
Drugs | Labs | Procedures
Software | Tutorials

Advertising
Links | Humor
Forum Archive
CME | Conferences

Privacy Statement
Terms & Conditions
Editorial Board
About us | Email

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.